Further Development. In the event that IntelGenx exercises its Transfer Option Pacific shall not, directly or indirectly, work outside of this Project, either alone or with any third party, on the development of a combination product containing both pentoxifylline and n-acetylcystein, for a period of twenty (20) years from the Effective Date of this Agreement, whether by carrying on or engaging in or being concerned with or interested in or advising, lending money to, guaranteeing the debts or obligations of or permitting its name or any part thereof to be used or employed by, any person engaged in or concerned with or interested in any business that is directly competitive with the a combination product containing both pentoxifylline and n-acetylcystein.
Appears in 2 contracts
Sources: Development and Commercialisation Agreement (Pacific Therapeutics Ltd.), Development and Commercialisation Agreement (Pacific Therapeutics Ltd.)